FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person * Touchon Pascal				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner				
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 05/18/2020						X Officer (give title below) Other (specify below) President and CEO						
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)		1	2. Transaction Date (Month/Day/Year)		on Date, if	f Code (Instr. 8)		(A) or I		rities Acquired Disposed of (D) , 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		Ownership Form:	Beneficial	
				(Month/Day/Year		Со	de	V	Amount	(A) or (D)	Price	(Instr. 3 a	·			Ownership (Instr. 4)
Commor	Stock		05/18/2020			St	1)		3,195	D	\$ 11.22 (2)	276,979)		D	
			Table II -				quire	cont the f d, Di	ained ir form dis	n this fo splays a of, or Be	orm are a curre	not requesting ntly valid		ormation spond unle rol numbe	ss	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative		on 3A. Deemed Execution Da	te, if 4.	4. Transaction Code		er ative ities	6. Date Exercisab and Expiration Da (Month/Day/Year		cisable on Date	7. Ti Amo Und Secu (Inst	itle and ount of derlying urities tr. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security	Beneficia Ownershi (Instr. 4)
	Security					Acqui (A) or Dispo of (D) (Instr. 4, and	sed				4)	Amount		Reported Transaction	Direct (I or Indirect) (I) (Instr. 4	ect

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Touchon Pascal C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X		President and CEO				

Signatures

/s/ David Tucker, Attorney-in-Fact for Pascal Touchon	05/20/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.
- (2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2020 and May 19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.